Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Infect Genet Evol ; 49: 157-163, 2017 04.
Article in English | MEDLINE | ID: mdl-28082188

ABSTRACT

The molecular epidemiology of HIV-1 in Iceland has not been described so far. Detailed analyses of the dynamics of HIV-1 can give insights for prevention of virus spread. The objective of the current study was to characterize the genetic diversity and transmission dynamics of HIV-1 in Iceland. Partial HIV-1 pol (1020bp) sequences were generated from 230 Icelandic samples, representing 77% of all HIV-1 infected individuals reported in the country 1985-2012. Maximum likelihood phylogenies were reconstructed for subtype/CRF assignment and determination of transmission clusters. Timing and demographic growth patterns were determined in BEAST. HIV-1 infection in Iceland was dominated by subtype B (63%, n=145) followed by subtype C (10%, n=23), CRF01_AE (10%, n=22), sub-subtype A1 (7%, n=15) and CRF02_AG (7%, n=15). Trend analysis showed an increase in non-B subtypes/CRFs in Iceland over the study period (p=0.003). The highest proportion of phylogenetic clustering was found among injection drug users (IDUs; 89%), followed by heterosexuals (70%) and men who have sex with men (35%). The time to the most recent common ancestor of the oldest subtype B cluster dated back to 1978 (median estimate, 95% highest posterior density interval: 1974-1981) suggesting an early introduction of HIV-1 into Iceland. A previously reported increase in HIV-1 incidence among IDUs 2009-2011 was revealed to be due to two separate outbreaks. Our study showed that a variety of HIV-1 subtypes and CRFs were prevalent in Iceland 1985-2012, with subtype B being the dominant form both in terms of prevalence and domestic spread. The rapid increase of HIV-1 infections among IDUs following a major economic crisis in Iceland raises questions about casual associations between economic factors, drug use and public health.


Subject(s)
Disease Outbreaks , Genotype , HIV Infections/epidemiology , HIV Infections/transmission , HIV-1/genetics , Phylogeny , Adult , Cluster Analysis , Drug Users/statistics & numerical data , Female , HIV Infections/virology , HIV-1/classification , HIV-1/isolation & purification , Heterosexuality/statistics & numerical data , Homosexuality, Male/statistics & numerical data , Humans , Iceland/epidemiology , Male , Middle Aged , Molecular Epidemiology , Molecular Typing , Prevalence , Risk Factors , Socioeconomic Factors
2.
Vaccine ; 26(47): 5967-72, 2008 Nov 05.
Article in English | MEDLINE | ID: mdl-18804140

ABSTRACT

We successfully re-vaccinated hepatitis B virus (HBV) vaccine non-responders using a double dose of the combined hepatitis A virus (HAV) and HBV vaccine. The hope was to improve priming of hepatitis B surface antigen (HBsAg)-specific cell mediated immune response (CMI) by an increased antigen dose and a theoretical adjuvant-effect from the local presence of a HAV-specific CMI. A few non-responders had a detectable HBsAg-specific CMI before re-vaccination. An in vitro detectable HBsAg-specific CMI was primed equally effective in non-responders (58%) as in first time vaccine recipients (68%). After the third dose a weak, albeit significant, association was observed between the magnitude of HBsAg-specific proliferation and anti-HBs levels. This regimen improves the priming of HBsAg-specific CMIs and antibodies.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Hepatitis A Vaccines , Hepatitis B Surface Antigens , Hepatitis B Vaccines , Vaccines, Combined , Hepatitis A Vaccines/administration & dosage , Hepatitis A Vaccines/immunology , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/immunology , Humans , Interferon-gamma/biosynthesis , Vaccines, Combined/administration & dosage , Vaccines, Combined/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...